Small Cell Lung Carcinoma clinical trials

Comparing two drugs for first-line treatment of advanced lung cancer

This trial tests a new drug called Rilvegostomig against the standard drug pembrolizumab (Keytruda) for people with advanced non-small cell lung cancer that has high levels of PD-L1 protein. The goal is to see which drug works better as a first treatment before any other cancer therapy.

T-DXd for advanced HER2-positive solid tumors

This trial is for people with advanced HER2-positive solid tumors (cancers that cannot be removed by surgery or have spread). It tests the drug T-DXd (also called Enhertu) when your doctor has already decided it's the right treatment for you and you have no other good options.

Study of amivantamab and olomorasib for KRAS G12C lung cancer

This trial tests a new combination of two targeted drugs (amivantamab and olomorasib) for people with advanced lung cancer that has a specific KRAS G12C mutation. It's for those whose cancer has grown despite prior chemotherapy and immunotherapy.

Study of amivantamab for advanced EGFR-mutated lung cancer

This study looks at how well a treatment called amivantamab works in people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). It aims to track real-world outcomes in patients who are starting amivantamab for the first time.

Study of PF-08634404 for early-stage or locally advanced lung cancer

This trial tests a new drug, PF-08634404, alone or with other treatments, for people with early-stage or locally advanced non-small cell lung cancer (NSCLC) that can be surgically removed or has been treated with radiation and chemo. It aims to find if the drug helps before or after surgery or after standard treatments.

Testing New Drug Combinations Before Lung Cancer Surgery

This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.

TDC treatment for advanced non-squamous lung cancer

This study is looking at how well a new treatment called TDC (which includes durvalumab and chemotherapy) works for people with a certain type of advanced lung cancer that has spread and has specific genetic features. It aims to see if this treatment is effective and safe in the real world, and it might be an option if you are starting this therapy anyway.

Vaccine plus Keytruda for lung cancer after surgery

This trial tests combining a cancer vaccine (V940) with the immunotherapy drug pembrolizumab (Keytruda) for people with non-small cell lung cancer that was treated with chemo and Keytruda before surgery but wasn't completely removed. The goal is to see if adding the vaccine helps prevent the cancer from coming back.

Immunotherapy after lung cancer surgery for those not getting chemo

This trial tests if the drug cemiplimab can prevent non-small cell lung cancer from coming back after surgery. It's for people whose tumors have PD-L1 levels of at least 1% and who are not receiving standard chemotherapy after surgery.

Study of IDE892 for advanced solid tumors with MTAP deletion

This study tests a new drug called IDE892, alone or in combination, for people with advanced solid tumors that have a specific genetic change (MTAP deletion). The goal is to see if the drug is safe and whether it can shrink tumors.

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Study of a new treatment for advanced cancers with a specific gene change

This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.

Study of a RAS-targeting pill for lung cancer

This trial tests a new daily pill (daraxonrasib/RMC-6236) for people with advanced non-small cell lung cancer that has a specific RAS mutation. It's for those who have already tried 1 or 2 previous treatments, including immunotherapy and chemotherapy.

Nivolumab at home vs. clinic for cancer treatment

This study compares giving the immunotherapy drug nivolumab as a shot under the skin at home versus in the clinic. It is for people with certain cancers who are already taking or starting nivolumab.

Study of ALX2004 for advanced solid tumors

This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

HER3-DXd for advanced solid tumors after prior treatment

This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.

Immunotherapy after surgery for lung cancer with no remaining cancer

This trial tests whether giving immunotherapy (durvalumab) after surgery can help prevent lung cancer from coming back if you already had a complete response to chemo and immunotherapy before surgery. It is for people with early-stage non-small cell lung cancer who had no cancer left after treatment.

Radioactive drug for advanced neuroendocrine and other cancers

This early-stage trial tests a new radioactive drug (called [212Pb]VMT-Alpha-NET) that targets a marker on certain cancer cells. It may help shrink or slow the growth of tumors that have spread or can't be removed, and it's being studied for several cancer types, including neuroendocrine tumors, small cell lung cancer, kidney cancer, and some head and neck cancers.

Study of new drugs for advanced lung cancer

This trial tests new treatments for people with stage IV nonsquamous non-small cell lung cancer that has gotten worse after prior immunotherapy and chemotherapy. It aims to find better options for those whose cancer has specific genetic features.

Targeted treatment for lung cancer with a MET gene change

This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.

Study of HLX43 for advanced non-small cell lung cancer

This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.

Cemiplimab and Fianlimab before lung cancer surgery

This trial tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before surgery can help treat stage IB to IIIB non-small cell lung cancer. You must have a PD-L1 level of at least 1% and your surgeon must think the tumor can be fully removed.

Study of PF-08046876 for advanced solid tumors

This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.